Key platelet abnormalities linked to neurodegenerative conditions
| Condition . | Key platelet abnormalities . | Species/model . | References . | 
|---|---|---|---|
| AD | Increased platelet activation | Human | 134 | 
| Impaired platelet degranulation | Human | 135 | |
| Platelet hyperactivity | APP23 mice | 96 | |
| Increased platelet adhesion to subendothelial matrix components | 3xTg-AD mice | 95 | |
| Increased platelet invasion into brain parenchyma | APP/PS1 mice | 72 | |
| Platelet inclusions in cerebral blood vessels | APP_SweDI mice | 136 | |
| Decreased platelet mitochondrial respiration rate | Human | 137 | |
| Platelet mitochondrial cytochrome oxidase deficiency | Human | 138 | |
| Reduced platelet mitochondrial pyruvate dehydrogenase & respiratory complex IV | Human | 139 | |
| Increased platelet β-secretase activity | Human | 140 | |
| Increased activity of τ | Human | 104,106,141 | |
| Increased secretion of amyloid β | Human | 93 | |
| Altered ratio of APP isoforms | Human | 103 | |
| Increased glycogen synthase kinase 3-β | Human | 142 | |
| Reduced glutamate uptake | Human | 143 | |
| PD | Increased mean platelet volume | Human | 144 | 
| Decreased platelet glutamate uptake | Human | 145 | |
| Reduction in platelet vesicular monoamine transporter 2 mRNA | Human | 146 | |
| Platelet mitochondrial dysfunction | Human | 147,148 | |
| Increased platelet monoamine oxidase B | MPTP mouse model | 149 | |
| HD | Increased platelet mHtt protein levels | Human | 150 | 
| Increased platelet aspartate and glycine levels | Human | 151 | |
| Impaired platelet adenosine A receptor signaling | Human | 152 | |
| Impaired platelet nitric oxide metabolism | Human | 153 | |
| Elevated platelet mitochondrial monoamine oxidase activity | Human | 141 | |
| ALS | Altered platelet mitochondrial membrane potential | Human | 154 | 
| Altered platelet mitochondrial morphology | Human | 155 | |
| Increased platelet TDP-43 levels | Human | 156 | |
| Reduced complex IV activity in platelet mitochondria | Human | 157 | |
| Decreased platelet serotonin levels | Human | 158 | |
| Increased glutamate synthase resulting in decreased glutamate uptake | Human | 159 | |
| Increased thrombospondin | Human | 160 | |
| MS | Increased platelet activation | Human | 161 | 
| Increased platelet adhesiveness | Human | 162 | |
| Increased PMP release | Human | 163 | |
| Altered serotonin release from dense granules | Human/EAE mice | 164 | |
| Altered lipid composition of platelet membranes (decreased cholesterol linoleate) | Human | 165 | 
| Condition . | Key platelet abnormalities . | Species/model . | References . | 
|---|---|---|---|
| AD | Increased platelet activation | Human | 134 | 
| Impaired platelet degranulation | Human | 135 | |
| Platelet hyperactivity | APP23 mice | 96 | |
| Increased platelet adhesion to subendothelial matrix components | 3xTg-AD mice | 95 | |
| Increased platelet invasion into brain parenchyma | APP/PS1 mice | 72 | |
| Platelet inclusions in cerebral blood vessels | APP_SweDI mice | 136 | |
| Decreased platelet mitochondrial respiration rate | Human | 137 | |
| Platelet mitochondrial cytochrome oxidase deficiency | Human | 138 | |
| Reduced platelet mitochondrial pyruvate dehydrogenase & respiratory complex IV | Human | 139 | |
| Increased platelet β-secretase activity | Human | 140 | |
| Increased activity of τ | Human | 104,106,141 | |
| Increased secretion of amyloid β | Human | 93 | |
| Altered ratio of APP isoforms | Human | 103 | |
| Increased glycogen synthase kinase 3-β | Human | 142 | |
| Reduced glutamate uptake | Human | 143 | |
| PD | Increased mean platelet volume | Human | 144 | 
| Decreased platelet glutamate uptake | Human | 145 | |
| Reduction in platelet vesicular monoamine transporter 2 mRNA | Human | 146 | |
| Platelet mitochondrial dysfunction | Human | 147,148 | |
| Increased platelet monoamine oxidase B | MPTP mouse model | 149 | |
| HD | Increased platelet mHtt protein levels | Human | 150 | 
| Increased platelet aspartate and glycine levels | Human | 151 | |
| Impaired platelet adenosine A receptor signaling | Human | 152 | |
| Impaired platelet nitric oxide metabolism | Human | 153 | |
| Elevated platelet mitochondrial monoamine oxidase activity | Human | 141 | |
| ALS | Altered platelet mitochondrial membrane potential | Human | 154 | 
| Altered platelet mitochondrial morphology | Human | 155 | |
| Increased platelet TDP-43 levels | Human | 156 | |
| Reduced complex IV activity in platelet mitochondria | Human | 157 | |
| Decreased platelet serotonin levels | Human | 158 | |
| Increased glutamate synthase resulting in decreased glutamate uptake | Human | 159 | |
| Increased thrombospondin | Human | 160 | |
| MS | Increased platelet activation | Human | 161 | 
| Increased platelet adhesiveness | Human | 162 | |
| Increased PMP release | Human | 163 | |
| Altered serotonin release from dense granules | Human/EAE mice | 164 | |
| Altered lipid composition of platelet membranes (decreased cholesterol linoleate) | Human | 165 | 
EAE, experimental autoimmune encephalomyelitis; mHtt, mutant huntingtin protein; PMP, platelet microparticle; TDP-43, TAR DNA-binding protein of 43 kDa.